Following dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ RAS inhibitor daraxonrasib has been
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy
FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN
FDA approves ‘game-changing’ pancreatic cancer drug
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | The Jerusalem Post
FDA approves new pancreatic cancer drug expected to usher in new era of treatment
Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by…
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
FDA approves Revolution Medicines' daraxonrasib (Rasonque) for second-line pancreatic cancer, after it nearly doubled survival in…
The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly…
FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials show a 60% reduced death risk vs…
